Sun Pharmaceuticals Industries' Q1 FY 2025-26 Quarterly Results

Result Summary

• Sun Pharmaceuticals Industries Ltd reported a 13.7% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Jun (Q1 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a growth of 8.6%.
• Its expenses for the quarter were up by 6.8% QoQ and 5.8% YoY.
• The net profit decreased 13.8% QoQ and decreased 19.8% YoY.
• The earnings per share (EPS) of Sun Pharmaceuticals Industries Ltd stood at 9.5 during Q1 FY 2025-26.

Financial Statments for Q1 FY 2025-26

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

Sun Pharmaceuticals Industries Ltd is a leading multinational pharmaceutical company based in India, primarily engaged in the manufacturing and marketing of pharmaceutical formulations and active pharmaceutical ingredients (APIs). The company's portfolio includes a wide range of products, including generics, branded generics, specialty products, over-the-counter (OTC) products, anti-retrovirals (ARVs), APIs, and intermediates. Sun Pharmaceuticals operates across various therapeutic segments such as cardiology, psychiatry, neurology, gastroenterology, and diabetology, among others. As a prominent player in the pharmaceutical industry, Sun Pharmaceuticals has a significant presence in both domestic and international markets, with a robust distribution network and research and development capabilities. There are no recent major developments available in the provided information.

Revenue

Sun Pharmaceuticals Industries Ltd reported a total income of ₹14,315.86 crores for Q1FY26, showing a quarter-over-quarter (QoQ) increase of 13.7% compared to ₹12,588.84 crores in Q4FY25. The year-over-year (YoY) increase from Q1FY25, where the total income was ₹13,185.30 crores, is 8.6%. The growth in total income for the current quarter suggests a positive trajectory in revenue generation. The financial data does not provide specific details regarding the breakdown of revenue streams or the contributing factors to this increase.

Profitability

The profit before tax for Sun Pharmaceuticals in Q1FY26 was ₹3,172.77 crores, representing a QoQ increase of 12.7% from ₹2,815.52 crores in Q4FY25. However, there is a YoY decrease of 7.3% compared to ₹3,423.50 crores in Q1FY25. The tax expense for Q1FY26 was ₹870.15 crores, significantly higher than both the previous quarter's ₹148.93 crores and the same quarter last year's ₹552.25 crores, marking increases of 484.3% QoQ and 57.6% YoY. The profit after tax for the current quarter was ₹2,292.87 crores, which is a decline of 13.8% QoQ from ₹2,658.74 crores in Q4FY25 and a 19.8% decrease YoY from ₹2,860.51 crores in Q1FY25. These figures indicate fluctuations in profitability over the periods analyzed.

Operating Metrics

The earnings per share (EPS) for Sun Pharmaceuticals in Q1FY26 stood at ₹9.50, reflecting a decrease of 14.4% QoQ from ₹11.10 in Q4FY25 and a decline of 19.5% YoY from ₹11.80 in Q1FY25. Total expenses for Q1FY26 were ₹10,325.09 crores, which is a 6.8% increase QoQ from ₹9,671.68 crores in Q4FY25 and a 5.8% increase YoY from ₹9,761.80 crores in Q1FY25. These metrics illustrate the company's operational dynamics and cost management over the quarters, highlighting changes in expenses and earnings per share. The data provided does not include specific information on other operating metrics like debt-to-equity ratio or current ratio.